FFR demonstrates a continuous and independent relationship with subsequent outcomes, modulated by medical therapy versus revascularization. Lesions with lower FFR values receive larger absolute benefits from revascularization. Measurement of FFR immediately after stenting also shows an inverse gradient of risk, likely from residual diffuse disease. An FFR-guided revascularization strategy significantly reduces events and increases freedom from angina with fewer procedures than an anatomy-based strategy.

Poor adherence to prescribed medication regimens remains an important challenge preventing successful treatment of cardiovascular diseases such as hypertension. While studies have documented differences in the time of day or weekday vs weekend on medication adherence, no study has examined whether having a medication-taking routine contributes to increased medication adherence. The purpose of this study was to: (1) identify patients’ sociodemographic factors associated with consistent medication-taking routine; (2) examine associations between medication-taking consistency, medication adherence, and blood pressure (BP) control. The study included black patients with hypertension (n = 190; 22 men and 168 women; age, mean±standard deviation 54 ± 12.08 years) who completed a practice-based randomized controlled trial. Findings showed that medication-taking consistency was significantly associated with better medication adherence (F = 9.54, P = .002). Associations with the consistency index were not statistically significant for diastolic BP control (odds ratio, 1.319; 95% confidence interval, 0.410–4.246; P = .642) and systolic BP control (odds ratio, 0.621; 95% confidence interval, 0.195–1.974; P = .419).

We know that endocardial mapping reports left ventricular electrical activity (voltage) B one marrow cell therapy for chronic ischemic heart failure has resulted in some evidence of left ventricular (LV) functional improvement upon metaanalysis. However, the magnitude of this effect is small and might not, in application, improve patient outcomes.1,2 Consistent with this notion, we found-in the Cardiovascular Cell Therapy Research Network's (CCTRN's) trial of First Mononuclear Cells injected in the United States (FOCUS) 3 -no detectable improvement in maximal oxygen consumption (Vo 2 max) or New York Heart Association (NYHA) functional class, despite a 2.7% increase in LV ejection fraction (LVEF) (difference between bone marrow mononuclear cell [BMC] and placebo groups [95% confidence interval (CI), 0.3-5.1, P=0.03]). Although there is promise, it is clear that a better un-

No abstract